Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab
暂无分享,去创建一个
S. Kako | Y. Kanda | M. Kurokawa | T. Motokura | S. Chiba | Koki Takahashi | A. Kamijo | Takuro Watanabe | S. Taniguchi | N. Hosoya | S. Miyakoshi | K. Oshima | Nahoko Nishimoto | Hiroyuki Sato
[1] J. Thachil,et al. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia. , 2007, Leukemia research.
[2] F. Noizat‐Pirenne,et al. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO‐incompatible allogeneic haematopoietic stem cell transplantation , 2007, Vox sanguinis.
[3] W. Ouwehand,et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology , 2007, Annals of Hematology.
[4] Y. Kanda,et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.
[5] S. Ogawa,et al. In Vivo Alemtuzumab Enables Haploidentical Human Leukocyte Antigen-Mismatched Hematopoietic Stem-Cell Transplantation Without Ex Vivo Graft Manipulation , 2005, Transplantation.
[6] R. Putzulu,et al. Rituximab for pure red cell aplasia after ABO‐mismatched allogeneic peripheral blood progenitor cell transplantation , 2005, Transfusion.
[7] C. Craddock,et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.
[8] S. Perrotta,et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. , 2003, Blood.
[9] H. Prince,et al. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. , 2003, Blood.
[10] B. Crowley,et al. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab , 2002, British journal of haematology.
[11] C. Craddock,et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.
[12] W. May,et al. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation , 2002, Bone Marrow Transplantation.
[13] M. Boeckh,et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. , 2001, Blood.
[14] D. Neuberg,et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. , 2000, Blood.
[15] M. Laffan,et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant , 1997, Bone Marrow Transplantation.
[16] J. Gottschall,et al. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.
[17] K. Neftel,et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. , 1990, Blood.
[18] I. Sniecinski,et al. IMMUNOHEMATOLOGIC CONSEQUENCES OF MAJOR ABOMISMATCHED BONE MARROW TRANSPLANTATION , 1988, Transplantation.
[19] P. Ness,et al. Probenecid induced immune hemolytic anemia. , 1986, The Journal of rheumatology.
[20] G. Garratty,et al. Immune hemolytic anemia associated with probenecid. , 1985, American journal of clinical pathology.